'On almost a daily basis I am being harassed and threatened by this person and nobody seems to want to do anything to protect me or my baby'
A woman says that she has been "left at risk" after being repeatedly threatened by a man who lives in her Belfast apartment block.
The man was arrested following this, but in the weeks afterwards he continued to harass and intimidate the woman. She said she reported these breaches of bail to police and that on one occasion after reporting threats it took officers 23 hours to attend. "On almost a daily basis I am being harassed and threatened by this person and nobody seems to want to do anything to protect me or my baby.
"Anytime this person is actually arrested, police drop them straight back at the apartment block and do nothing to protect me or the others who are living here. Community worker Tarlach Mac Dhónaill from the North Belfast IRSP has said that they have been supporting the woman through this difficult time and expressed disappointment that she has been left in this position.
"Playing loud music until 5am in the morning while banging on the floor in order to disrupt an infant should be dealt with as child abuse and it is disgusting that the police appear to be providing this man with more protection than the mother and baby.A PSNI spokesperson said that police received a report of criminal damage being caused to the front door of the property.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why pace may be more important than step count when walkingIf you’re looking to get the most out of your daily constitutional, then step count isn’t the only thing to keep in mind.
Read more »
Beach from Leonardo DiCaprio film to be restored after being ruined by movieThousands of tourists flocked to the beauty spot on a daily basis, leaving the coral reef to be re-attached using superglue.
Read more »
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia | Journal of Clinical OncologyPURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3mut AML. METHODS This phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505) enrolled patients with FLT3 wild-type and FLT3mut (escalation) or FLT3mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III–defined response criteria. RESULTS Sixty-one patients were enrolled (n=56 FLT3mut); 64% (n=36 of 56) of FLT3mut patients had received prior FLT3 inhibitor therapy. The recommended phase II dose was 400 mg venetoclax once daily and 120 mg gilteritinib once daily. The most common grade 3/4 adverse events were cytopenias (n=49; 80%). Adverse events prompted venetoclax and gilteritinib dose interruptions in 51% and 48%, respectively. The mCRc rate for FLT3mut patients was 75% (CR, 18%; CR with incomplete blood count recovery, 4%; CR with incomplete platelet recovery, 18%; and morphologic leukemia-free state, 36%) and was similar among patients with or without prior FLT3 inhibitor therapy (80% v 67%, respectively). The median follow-up was 17.5 months. The median time to response was 0.9 months, and the median remission duration was 4.9 months (95% CI, 3.4 to 6.6). FLT3 molecular response (| 10−2) was achieved in 60% of evaluable mCRc patients (n=15 of 25). The median overall survival for FLT3mut patients was
Read more »
What's On Editor - LiveIt’s an exciting time at Reach, due to our sustained growth and our committed future growth plans, we are now looking for a What’s On Editor to join our Live team in Scotland. Our three city news sites in Glasgow, Edinburgh and Aberdeen are already the most popular local news sites in their respective markets and you can play a key role in taking them to even greater heights. This role will involve both writing and curating and editing content about all that’s going on in our cities, from food and drink to music and theatre, nightlife to family-friendly events. The Editor will manage content, develop existing teams and ensure audience targets are delivered every month. We’re looking for fresh ideas and new perspectives from people from a wide range of backgrounds, and we want you to tell us the stories you believe are important from our many communities so we can continue to diversify our content. So, who are we? The Daily Record is part of Reach Plc. You might not have heard of us but we have probably met without you even realising it. We are home to Scotland and the UK’s most iconic digital platforms, magazines and newspapers. From the Daily Record and Sunday Mail to the Scottish Daily Express, Glasgow Live, Edinburgh Live and OK!. We also own a huge number of regional titles across the UK such as the Paisley Daily Express, Ayrshire Post, Liverpool Echo, BirminghamLive and the Manchester Evening News (plus lots more). Our brands and the stories we cover are as varied as our people. We help all kinds of people share experiences through our stories because we believe this is what makes us human. Oh, and we should probably also mention that with a monthly readership of 47 million people, Reach is the largest commercial publisher in the UK. At Reach, not only will you feel better understood, you will also feel you understand other people better too. This role is home and hub based and can be linked to one of our 3 Scotland Hubs (Glasgow, Edinburgh or Aberdeen). We are
Read more »